512 related articles for article (PubMed ID: 28282300)
1. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Arribas JR; Thompson M; Sax PE; Haas B; McDonald C; Wohl DA; DeJesus E; Clarke AE; Guo S; Wang H; Callebaut C; Plummer A; Cheng A; Das M; McCallister S
J Acquir Immune Defic Syndr; 2017 Jun; 75(2):211-218. PubMed ID: 28282300
[TBL] [Abstract][Full Text] [Related]
2. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Wohl D; Oka S; Clumeck N; Clarke A; Brinson C; Stephens J; Tashima K; Arribas JR; Rashbaum B; Cheret A; Brunetta J; Mussini C; Tebas P; Sax PE; Cheng A; Zhong L; Callebaut C; Das M; Fordyce M;
J Acquir Immune Defic Syndr; 2016 May; 72(1):58-64. PubMed ID: 26829661
[TBL] [Abstract][Full Text] [Related]
3. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.
Bonora S; Calcagno A; Trentalange A; Di Perri G
Expert Opin Pharmacother; 2016; 17(3):409-19. PubMed ID: 26642079
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
[TBL] [Abstract][Full Text] [Related]
5. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Hodder S; Squires K; Kityo C; Hagins D; Avihingsanon A; Kido A; Jiang S; Kulkarni R; Cheng A; Cao H
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):209-213. PubMed ID: 29481486
[TBL] [Abstract][Full Text] [Related]
6. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
[TBL] [Abstract][Full Text] [Related]
7. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Sun L; He Y; Xu L; Zhao F; Zhou Y; Zhang L; Peng Q; Zhang H; Zhang Q; Cao T; Song Y; Wang S; Rao M; Jia X; Liu X; Zhou J; Ju B; Wang H; Liu J
J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S8-S15. PubMed ID: 36094509
[TBL] [Abstract][Full Text] [Related]
8. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
[TBL] [Abstract][Full Text] [Related]
9. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Orkin C; Eron JJ; Rockstroh J; Podzamczer D; Esser S; Vandekerckhove L; Van Landuyt E; Lathouwers E; Hufkens V; Jezorwski J; Opsomer M;
AIDS; 2020 Apr; 34(5):707-718. PubMed ID: 31833849
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Sax PE; Zolopa A; Brar I; Elion R; Ortiz R; Post F; Wang H; Callebaut C; Martin H; Fordyce MW; McCallister S
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):52-8. PubMed ID: 24872136
[TBL] [Abstract][Full Text] [Related]
11. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione SA; Cherian SM; Özdener AE
J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
[TBL] [Abstract][Full Text] [Related]
12. Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Margot NA; Kitrinos KM; Fordyce M; McCallister S; Miller MD; Callebaut C
HIV Clin Trials; 2016 Mar; 17(2):78-87. PubMed ID: 26892863
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
Rockstroh JK; DeJesus E; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Plummer A; Abram M; Cheng AK; Fordyce MW; Szwarcberg J;
J Acquir Immune Defic Syndr; 2013 Apr; 62(5):483-6. PubMed ID: 23337366
[TBL] [Abstract][Full Text] [Related]
14. Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients.
Huang YS; Cheng CY; Sun HY; Cheng SH; Lu PL; Lee CH; Lee YT; Tsai HC; Yang CJ; Liu CE; Liou BH; Lin SP; Huang SH; Ho MW; Tang HJ; Hung CC;
Microbiol Spectr; 2023 Jun; 11(3):e0512522. PubMed ID: 36988457
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S
J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913
[TBL] [Abstract][Full Text] [Related]
16. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
18. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
[TBL] [Abstract][Full Text] [Related]
19. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
20. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
Pozniak A; Arribas JR; Gathe J; Gupta SK; Post FA; Bloch M; Avihingsanon A; Crofoot G; Benson P; Lichtenstein K; Ramgopal M; Chetchotisakd P; Custodio JM; Abram ME; Wei X; Cheng A; McCallister S; SenGupta D; Fordyce MW;
J Acquir Immune Defic Syndr; 2016 Apr; 71(5):530-7. PubMed ID: 26627107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
